SCHEMBL7050294

SCHEMBL7050294

CC(O)NS(=O)(=O)c1cc[c]cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 3/20 0.40
MMP2 P08253 9/20 0.39
CA9 Q16790 4/20 0.39
CA12 O43570 3/20 0.39
CA14 Q9ULX7 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MMP3 P08254 7/20 0.38
MMP13 P45452 7/20 0.38
MMP1 P03956 6/20 0.38
MMP7 P09237 6/20 0.38
MMP9 P14780 6/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CA2 P00918 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
CA1 P00915 1/20 0.37
CA7 P43166 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1570351 0.84 NPSR1 (0.47) CA9CA12SMN1; SMN2NPSR1CA2
SCHEMBL6130629 0.78 MMP2 (0.61) MMP2CA9CA12CA14SMN1; SMN2
SCHEMBL3971060 0.78 SMN1; SMN2 (0.37) ADAMTS4MMP2CA9CA12CA14
SCHEMBL6441675 0.77 MMP1 (0.58) MMP2MMP3MMP13MMP1MMP7
SCHEMBL9579887 0.74 CA9 (0.53) ADAMTS4MMP2CA9CA12MMP3
SCHEMBL28001091 0.74 GAA (0.45) CA9CA12SMN1; SMN2CA2ALDH1A1
SCHEMBL3974092 0.74 SMN1; SMN2 (0.41) ADAMTS4CA9CA12SMN1; SMN2NPSR1
SCHEMBL11595081 0.74 MMP1 (0.30) MMP13MMP1
SCHEMBL15904139 0.73 MMP9 (0.44) ADAMTS4MMP2CA9CA12CA14
SCHEMBL28001099 0.73 SMN1; SMN2 (0.50) CA9CA12SMN1; SMN2CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US claimed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP claimed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO claimed
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 ADAMTS4 28/4885MMP2 8/4885CA9 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.